Tagged with J

Saudi Arabia Following on from our list of the overall top 10 companies in the Saudi Arabian pharma market, here PharmaBoardroom highlights some of the top domestic companies in the USD 8.2 billion Saudi pharma market, many of which are now well-established and carving out international footprints.   Tabuk Pharmaceuticals Founded in…

Norway Filip Standaert outlines the significance of the Nordic cluster to J&J’s medical device operations in Europe, how the affiliate responded to the COVID-19 crisis, and the ways in which J&J is aiming to contribute to driving efficiencies within the Norwegian healthcare system.   There is still change management to be…

Japan Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known player may be Taiho Pharmaceutical, a Japanese specialty pharma player that was a pioneer in the field of oral chemotherapy, led by president Masayuki Kobayashi. The company also works in the areas of allergy and…

Global Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from Janssen’s Ebola vaccine; and his key message to the global community on vaccines.   We need to be sure we are not complacent. We have to keep an…

Japan Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019.   The company’s central philosophy of human health care (hhc) was introduced in 1992 by current director, representative corporate officer and…

South Africa South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share price as well as its global profile.   Aspen is best known internationally for bringing generic antiretrovirals for HIV to…

Norway Janssen Norway’s Mario Klesse shares his first impressions of the Norwegian pharma market, his strategic priorities for the affiliate, how Janssen is defining and meeting unmet patient needs, key access challenges, and the importance of bringing more clinical trials to Norway.   We will only see the massive advantages of…

China While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in 2003! Gendicine® was a gene therapy for the treatment of haemophilia B. While China mostly lost the advantage of that…

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive major medical advances and new treatments.   Here’s what we know today and what we’ll need to do tomorrow to benefit from the promises…

Switzerland Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients, as well as his perspectives on talent development within the industry.   Switzerland is very open to innovative products, and…

UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…

Roundup The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy can kickstart the domestic Filipino pharma industry.   Alvotech and DKSH have expanded their partnership to commercialize six new biosimilar…